Key Highlights
- Shares trading up 2.94% to $2.83 in today's session.
- Trading Volume reached 3.96 million shares.
- The company reported an EPS of negative $0.75.
- Preclinical data showed a roughly 90% reduction in LDL cholesterol sustained over ten months in animal studies.
Regulatory Clearance Received for First-in-Human Trial
Editas Medicine, Inc. (NASDAQ:EDIT), a gene editing company built around CRISPR technology, received regulatory and ethics approval in Australia to begin its first-in-human Strive trial of EDIT-401, an experimental in vivo gene editing treatment designed to lower LDL cholesterol in patients with a genetic high-cholesterol disorder known as heterozygous familial hypercholesterolemia.
New Preclinical Data to Be Presented at Cardiology Conference
The company also announced new preclinical data showing the treatment maintained a roughly 90% reduction in LDL cholesterol over ten months in non-human primate studies. The data will be presented at a major cardiology conference in November, adding further support to the therapy's potential durability.
Shares Rise on Trial Progress
Shares rose today, with an EPS of negative $0.75 reflecting the company's clinical-stage status ahead of any approved products. The company said it remains on track to begin patient dosing this year, with initial safety and tolerability data expected in the first quarter of 2027.
Outlook: Trial Expansion to New Zealand Still Under Review
A related regulatory submission is still under review in New Zealand, which could expand the pool of eligible trial sites if approved. With dosing expected to begin soon, investors may watch for early safety signals from the trial's first patients.
FAQs
Q: Why did Editas Medicine stock rise today?
A: Shares rose 2.94% after the company received regulatory approval in Australia to begin a first-in-human trial of its gene editing treatment for high cholesterol.
Q: What condition is the trial targeting?
A: The trial targets heterozygous familial hypercholesterolemia, a genetic disorder that causes significantly elevated LDL cholesterol levels.
Q: When is initial trial data expected?
A: The company expects to report initial safety and tolerability data in the first quarter of 2027.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.